Camlin Fine Sciences reported a consolidated net loss of ₹336.22 million for the quarter ended June 30, 2026, compared to a net loss of ₹106.81 million in the corresponding quarter of the previous financial year. The standalone entity recorded a net loss of ₹123.12 million for the quarter, up from a loss of ₹106.81 million in Q1FY26. The deterioration in profitability was primarily driven by significant foreign exchange losses and exceptional items related to insurance claim settlements, which offset the growth in operating revenues. On a consolidated basis, EBITDA contracted sharply to ₹93 million from ₹190 million in the year-ago period, with EBITDA margin narrowing to 1.79% from 4.49%.

The Board of Directors approved the unaudited financial results at a meeting held on August 11, 2026, in compliance with Regulation 30 and Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The results were reviewed by the Audit Committee and subjected to a limited review by the statutory auditors, Kalyaniwalla & Mistry LLP. The company also disclosed that it has restructured its segment reporting to reflect three distinct business units: Specialty Ingredients, Aroma, and Performance Chemicals & Others.

Consolidated revenue from operations surged 27.50% year-on-year to ₹5,198.79 million, rising from ₹4,077.21 million in Q1FY26. Standalone revenue also grew 16.20% to ₹2,224.86 million from ₹1,914.38 million in the prior year period. However, total expenses increased disproportionately. Standalone total expenses rose to ₹2,425.60 million from ₹2,115.04 million, while consolidated expenses climbed to ₹5,437.65 million from ₹4,184.18 million. This cost inflation resulted in a pre-tax loss from continuing operations of ₹322.59 million on a consolidated basis, compared to a loss of ₹31.79 million in the same quarter last year.

Key Financial Metrics

The following table summarises the standalone and consolidated financial performance for the quarter:

Segment Performance

The Specialty Ingredients segment remained the primary revenue driver, contributing ₹4,013.17 million to gross segment revenue, up from ₹2,936.08 million in Q1FY26. The Aroma segment saw robust growth, with revenue jumping to ₹774.07 million from ₹566.88 million. Performance Chemicals & Others contributed ₹1,748.90 million. While Specialty Ingredients generated a positive segment result of ₹254.66 million, the Aroma segment incurred a loss of ₹33.81 million, and Performance Chemicals & Others posted a loss of ₹44.41 million.

What the Numbers Show

The widening consolidated loss and sharp EBITDA contraction are largely attributable to non-operational factors rather than core operational inefficiencies. The company recorded a foreign exchange loss of ₹83.69 million under finance costs, significantly impacting the bottom line. Additionally, an exceptional item of ₹108.80 million was recognised due to a shortfall in the settlement of an insurance claim regarding a fire incident at CFS Do Brasil Industria in February 2026. These one-off charges masked the underlying revenue growth, indicating that the operational engine is expanding even as external financial headwinds compress net margins.

Other Developments

The company completed the acquisition of minority stakes in Vinpai S.A., increasing its holding to 95.41% following an open offer that closed on July 6, 2026. The transaction involved the transfer of 501,842 equity shares for ₹194.63 million. Furthermore, management confirmed that the loss from machinery and inventory due to a fire at the Diphenol manufacturing unit in Dahej on May 23, 2026, amounting to ₹67.03 million, is fully covered by insurance claims, with no residual loss expected. The liquidation process of CFS Europe SpA continues, with legal expenses of ₹2.50 million booked under discontinued operations.

Camlin Fine Sciences Limited shareholders approved the company’s audited financial statements for the fiscal year ended March 31, 2026, and reappointed two non-executive directors at its 33rd Annual General Meeting (AGM) held on August 11, 2026. The meeting, chaired by Chairman and Managing Director Ashish Dandekar, was conducted through Video Conferencing (VC) / Other Audio Visual Means (OAVM) in compliance with Ministry of Corporate Affairs and Securities and Exchange Board of India (SEBI) circulars. All four resolutions placed before the shareholders were passed with requisite majority, reflecting strong support from both promoter and public stakeholders.

The AGM transacted ordinary business including the adoption of standalone and consolidated financial statements for FY26, alongside the re-appointment of Harsha Raghavan and Jens Van Nieuwenborgh as Non-Executive Non-Independent Directors, who retired by rotation. Under special business, shareholders ratified the remuneration of the Cost Auditor for the financial year ending March 31, 2027. The proceedings were scrutinized by Jayant Ranade of JHR & Associates, appointed as Scrutinizer pursuant to Section 108 of the Companies Act, 2013 and Regulation 44 of the SEBI Listing Regulations.

Voting participation was robust, with 56.83% of outstanding shares polled across all resolutions. Promoter and Promoter Group shareholders, holding 92,264,053 shares, voted in favor of all resolutions with 100% support. Public Institutional shareholders also demonstrated high engagement, polling over 84% of their holdings. Remote e-voting was open from August 8 to August 10, 2026, while additional voting occurred during the live meeting session.

Voting Results Summary

The Statutory Auditor’s report contained no qualifications or adverse remarks, as noted by the Chairman during the proceedings. The Scrutinizer’s consolidated report confirmed that no invalid votes were identified during the scrutiny process. A limited number of abstentions were recorded for specific resolutions but were classified separately as votes not cast.

What the Numbers Show

The near-unanimous approval of all resolutions underscores stable shareholder confidence in Camlin Fine Sciences’ governance structure. The promoter group’s complete alignment with all proposals, combined with high institutional participation, suggests minimal dissent regarding the company’s strategic direction and financial reporting for FY26. The negligible percentage of votes against any resolution indicates broad consensus among equity holders.